A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection In Vitro and In Vivo | Zendy

Anne Moscona | Zendy; Matteo Porotto | Zendy; Samantha G. Palmer | Zendy; Caroline G. Tai | Zendy; L. M. Aschenbrenner | Zendy; Gallen TrianaBaltzer | Zendy; QiXiang Li | Zendy; David F. Wurtman | Zendy; Stefan Niewiesk | Zendy; Fang Fang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection In Vitro and In Vivo

Author(s) -

Anne Moscona,

Matteo Porotto,

Samantha G. Palmer,

Caroline G. Tai,

L. M. Aschenbrenner,

Gallen TrianaBaltzer,

QiXiang Li,

David F. Wurtman,

Stefan Niewiesk,

Fang Fang

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/653621

Subject(s) - sialic acid , sialidase , receptor , in vivo , biology , in vitro , microbiology and biotechnology , virology , glycoprotein , respiratory epithelium , virus , neuraminidase , epithelium , biochemistry , genetics

The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface of respiratory epithelial cells via interaction between viral receptor-binding molecules and sialic acid-containing receptors. DAS181, a recombinant sialidase protein containing the catalytic domain of Actinomyces viscosus sialidase, removes cell surface sialic acid, and we proposed that it would inhibit HPIV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research